Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Carlo A. Altamura; Fulgenzio Colacurcio; Massimo C. Kauri; Anna R. Moro; Fedele De Novellis

doi:10.1016/0278-5846(90)90061-K

Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Carlo A. Altamura, Fulgenzio Colacurcio, Massimo C. Kauri, Anna R. Moro, Fedele De Novellis

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p <0.01) higher EPSE total scores compared to those with a duration of illness <10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.

Original language	English
Pages (from-to)	25-35
Number of pages	11
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	14
Issue number	1
DOIs	https://doi.org/10.1016/0278-5846(90)90061-K
Publication status	Published - 1990

Keywords

C
catatonic
D
DG
diagnosis
disorganized
EPSE
extrapyramidal side-effects rating scale
haioperidol decanoate
haloperidol
haloperidol decanoate
HL
HL-D
L/D
level/dose ratio
not performed
NP
P
paranoid
patient
pharmacokinetics
PL
plasma levels
PT
schizophrenia
SD
standard deviation
U
undifferentiated
years
yrs

ASJC Scopus subject areas

Biological Psychiatry
Pharmacology

Access to Document

10.1016/0278-5846(90)90061-K

Cite this

@article{acd177b0aa8946bdbe4730f7ae73ec27,

title = "Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels",

abstract = "1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p <0.01) higher EPSE total scores compared to those with a duration of illness <10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.",

keywords = "C, catatonic, D, DG, diagnosis, disorganized, EPSE, extrapyramidal side-effects rating scale, haioperidol decanoate, haloperidol, haloperidol decanoate, HL, HL-D, L/D, level/dose ratio, not performed, NP, P, paranoid, patient, pharmacokinetics, PL, plasma levels, PT, schizophrenia, SD, standard deviation, U, undifferentiated, years, yrs",

author = "Altamura, {Carlo A.} and Fulgenzio Colacurcio and Kauri, {Massimo C.} and Moro, {Anna R.} and {De Novellis}, Fedele",

year = "1990",

doi = "10.1016/0278-5846(90)90061-K",

language = "English",

volume = "14",

pages = "25--35",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Haloperidol decanoate in chronic schizophrenia

T2 - A study of 12 months with plasma levels

AU - Altamura, Carlo A.

AU - Colacurcio, Fulgenzio

AU - Kauri, Massimo C.

AU - Moro, Anna R.

AU - De Novellis, Fedele

PY - 1990

Y1 - 1990

N2 - 1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p <0.01) higher EPSE total scores compared to those with a duration of illness <10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.

AB - 1. 1. Clinical activity, extrapyramidal side-effects were evaluated in 22 schizophrenic out patients diagnosed according to DSM III and treated with haioperidol decanoate (50-300 mg i.m. monthly dose) for 12 months. 2. 2. BPRS total scores did not show significant fluctuations showing a clinical stability of the patient population. 3. 3. Patients with a duration of illness > 10 yrs (Group 2) showed significant (p <0.01) higher EPSE total scores compared to those with a duration of illness <10 yrs (Group 1). 4. 4. A positive correlation was found between the administered dose and haloperidol plasma levels. 5. 5. Patients from Group 2 reached the steady-state more slowly and showed a lower total L/D ratio compared to those from Group 1. 6. 6. The pharmacokinetic approach seems desirable in order to adjust the dose and avoid schizophrenic relapses.

KW - C

KW - catatonic

KW - D

KW - DG

KW - diagnosis

KW - disorganized

KW - EPSE

KW - extrapyramidal side-effects rating scale

KW - haioperidol decanoate

KW - haloperidol

KW - haloperidol decanoate

KW - HL

KW - HL-D

KW - L/D

KW - level/dose ratio

KW - not performed

KW - NP

KW - P

KW - paranoid

KW - patient

KW - pharmacokinetics

KW - PL

KW - plasma levels

KW - PT

KW - schizophrenia

KW - SD

KW - standard deviation

KW - U

KW - undifferentiated

KW - years

KW - yrs

UR - http://www.scopus.com/inward/record.url?scp=0025056685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025056685&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(90)90061-K

DO - 10.1016/0278-5846(90)90061-K

M3 - Article

C2 - 1967847

AN - SCOPUS:0025056685

VL - 14

SP - 25

EP - 35

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -

Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this